Anvisa and Butantan study trivalent vaccine against covid-19

During the meeting, the bodies analyzed information about an updated version of Coronavac, manufactured by Chinese biopharmaceutical company Sinovac.

According to Butantan, to date, data on this production are still preliminary, as Sinovac has only conducted two pre-clinical studies. The tests were only carried out on animals, but Sinovac is already recruiting volunteers to continue with the human testing stage.

Anvisa took the opportunity to signal which points should be observed in a future authorization request for the trivalent vaccine against Covid-19.

The Butantan Institute left its commitment to formalize, with Anvisa, the data that is currently available on the new vaccine and also the planning proposed by Sinovac regarding the next phases of clinical studies. Then, the regulatory agency must analyze the proposals.

Source: Estadão Content

See also:

40 of Brazil's 118 health macro-regions have a high rate of Covid-19 cases, says Instituto Todos pela Saúde

According to the Todos pela Saúde Institute (ITpS), in a report released this Thursday (8), 33,9% of Brazilian macro-regions showed an increase in the rate of weekly cases of covid-19 at the beginning of December. Using data from the Ministry of Health, ITpS identified that of the 118 macro-regions in Brazil, 40 had a high number of contaminations. The high rates are mainly in the states of Espírito Santo, Minas Gerais, Santa Catarina, Paraíba and Distrito Federal. O Curto News is a partner with ITpS to disseminate accurate and uncomplicated information about Covid-19.